Home
>
US Stocks
>
NovoCure Limited

NovoCure Limited (NVCR)

$48.66

+1.66

(+3.53%)▲

Market is closed - opens 7 PM, 08 Jun 2023

Insights on NovoCure Ltd

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 140.86M → 122.18M (in $), with an average decrease of 4.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -4.64M → -53.06M (in $), with an average decrease of 127.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 28.0% return, outperforming this stock by 68.1%

  • Vs SYK

    In the last 3 years, Stryker Corp. has given 30.5% return, outperforming this stock by 61.5%

Performance

  • $45.77
    $48.91
    $48.66
    downward going graph

    5.94%

    Downside

    Day's Volatility :6.42%

    Upside

    0.51%

    downward going graph
  • $46.06
    $120.03
    $48.66
    downward going graph

    5.34%

    Downside

    52 Weeks Volatility :61.63%

    Upside

    59.46%

    downward going graph

Returns

PeriodNovoCure LimitedSector (Health Care)Index (Russel 2000)
3 Months
-37.23%
2.1%
-5.8%
6 Months
-37.62%
-6.4%
-2.1%
1 Year
-40.14%
-1.4%
-7.8%
3 Years
-32.97%
25.7%
17.4%

Highlights

Market Capitalization
8.7B
Book Value
$4.07
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.4
PEG Ratio
-0.47
Wall Street Target Price
97.71
Profit Margin
-26.98%
Operating Margin TTM
-28.4%
Return On Assets TTM
-7.98%
Return On Equity TTM
-32.47%
Revenue TTM
522.5M
Revenue Per Share TTM
4.97
Quarterly Revenue Growth YOY
-11.200000000000001%
Gross Profit TTM
423.6M
EBITDA
-138.7M
Diluted Eps TTM
-1.4
Quarterly Earnings Growth YOY
-0.06
EPS Estimate Current Year
-1.93
EPS Estimate Next Year
-2.11
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Sell
    23%Buy
    30%Hold
    46%Sell
Based on 13 Wall street analysts offering stock ratings for NovoCure Limited(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
3
3
8
Hold
4
4
4
Sell
6
6
2

Analyst Forecast

What analysts predicted

Upside of 100.8%

Current $48.66
Target $97.71

Company Financials

FY17Y/Y Change
Revenue
177.0M
↑ 113.57%
Net Income
-61.7M
↓ 53.23%
Net Profit Margin
-34.83%
↑ 124.23%
FY18Y/Y Change
Revenue
248.1M
↑ 40.13%
Net Income
-63.6M
↑ 3.08%
Net Profit Margin
-25.62%
↑ 9.21%
FY19Y/Y Change
Revenue
351.3M
↑ 41.62%
Net Income
-7.2M
↓ 88.62%
Net Profit Margin
-2.06%
↑ 23.56%
FY20Y/Y Change
Revenue
494.4M
↑ 40.72%
Net Income
19.8M
↓ 373.97%
Net Profit Margin
4.01%
↑ 6.07%
FY21Y/Y Change
Revenue
535.0M
↑ 8.23%
Net Income
-58.4M
↓ 394.58%
Net Profit Margin
-10.91%
↓ 14.92%
FY22Y/Y Change
Revenue
537.8M
↑ 0.53%
Net Income
-92.5M
↑ 58.58%
Net Profit Margin
-17.2%
↓ 6.29%
Q4 FY21Q/Q Change
Revenue
133.2M
↓ 0.29%
Net Income
-26.5M
↑ 101.6%
Net Profit Margin
-19.86%
↓ 10.04%
Q1 FY22Q/Q Change
Revenue
137.5M
↑ 3.25%
Net Income
-4.6M
↓ 82.44%
Net Profit Margin
-3.38%
↑ 16.48%
Q2 FY22Q/Q Change
Revenue
140.9M
↑ 2.41%
Net Income
-24.0M
↑ 416.63%
Net Profit Margin
-17.04%
↓ 13.66%
Q3 FY22Q/Q Change
Revenue
131.0M
↓ 7.01%
Net Income
-26.6M
↑ 10.7%
Net Profit Margin
-20.29%
↓ 3.25%
Q4 FY22Q/Q Change
Revenue
128.4M
↓ 1.96%
Net Income
-37.3M
↑ 40.36%
Net Profit Margin
-29.05%
↓ 8.76%
Q1 FY23Q/Q Change
Revenue
122.2M
↓ 4.86%
Net Income
-53.1M
↑ 42.24%
Net Profit Margin
-43.43%
↓ 14.38%
FY17Y/Y Change
Total Assets
265.3M
↓ 5.95%
Total Liabilities
151.7M
↑ 8.59%
FY18Y/Y Change
Total Assets
339.8M
↑ 28.08%
Total Liabilities
227.5M
↑ 49.96%
FY19Y/Y Change
Total Assets
479.4M
↑ 41.1%
Total Liabilities
261.7M
↑ 15.0%
FY20Y/Y Change
Total Assets
1.1B
↑ 119.42%
Total Liabilities
575.5M
↑ 119.93%
FY21Y/Y Change
Total Assets
1.1B
↑ 8.32%
Total Liabilities
729.0M
↑ 26.68%
FY22Y/Y Change
Total Assets
80.1M
↓ 92.97%
Total Liabilities
750.5M
↑ 2.95%
Q4 FY21Q/Q Change
Total Assets
1.1B
↑ 1.7%
Total Liabilities
729.0M
↑ 3.07%
Q1 FY22Q/Q Change
Total Assets
1.2B
↑ 0.94%
Total Liabilities
714.3M
↓ 2.01%
Q2 FY22Q/Q Change
Total Assets
1.2B
↑ 1.08%
Total Liabilities
721.0M
↑ 0.93%
Q3 FY22Q/Q Change
Total Assets
1.2B
↑ 0.99%
Total Liabilities
728.8M
↑ 1.08%
Q4 FY22Q/Q Change
Total Assets
80.1M
↓ 93.18%
Total Liabilities
750.5M
↑ 2.97%
Q1 FY23Q/Q Change
Total Assets
1.2B
↑ 1365.74%
Total Liabilities
742.2M
↓ 1.1%
FY17Y/Y Change
Operating Cash Flow
-33.1M
↓ 69.2%
Investing Cash Flow
8.6M
↓ 33.61%
Financing Cash Flow
5.2M
↓ 93.12%
FY18Y/Y Change
Operating Cash Flow
-1.9M
↓ 94.37%
Investing Cash Flow
-5.5M
↓ 163.66%
Financing Cash Flow
69.4M
↑ 1242.28%
FY19Y/Y Change
Operating Cash Flow
26.6M
↓ 1527.35%
Investing Cash Flow
-51.7M
↑ 840.6%
Financing Cash Flow
61.7M
↓ 11.08%
FY20Y/Y Change
Operating Cash Flow
99.1M
↑ 272.46%
Investing Cash Flow
-472.8M
↑ 815.18%
Financing Cash Flow
440.2M
↑ 613.69%
FY21Y/Y Change
Operating Cash Flow
82.8M
↓ 16.53%
Investing Cash Flow
-144.8M
↓ 69.37%
Financing Cash Flow
25.7M
↓ 94.16%
FY22Y/Y Change
Operating Cash Flow
30.8M
↓ 62.8%
Investing Cash Flow
-140.0M
↓ 3.37%
Financing Cash Flow
15.5M
↓ 39.73%
Q4 FY21Q/Q Change
Operating Cash Flow
14.4M
↓ 40.97%
Investing Cash Flow
-499.1M
↓ 264.88%
Financing Cash Flow
3.7M
↑ 20.29%
Q1 FY22Q/Q Change
Operating Cash Flow
-3.7M
↓ 125.6%
Investing Cash Flow
-17.4M
↓ 96.51%
Financing Cash Flow
3.1M
↓ 13.99%
Q2 FY22Q/Q Change
Operating Cash Flow
15.8M
↓ 527.5%
Investing Cash Flow
155.8M
↓ 994.64%
Financing Cash Flow
4.7M
↑ 50.78%
Q3 FY22Q/Q Change
Operating Cash Flow
22.4M
↑ 42.24%
Investing Cash Flow
-150.2M
↓ 196.46%
Financing Cash Flow
4.2M
↓ 11.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.7M
↓ 116.53%
Investing Cash Flow
-128.1M
↓ 14.77%
Financing Cash Flow
3.4M
↓ 18.89%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.7M
↑ 351.23%
Investing Cash Flow
82.3M
↓ 164.26%
Financing Cash Flow
5.2M
↑ 52.61%

Technicals Summary

Sell

Neutral

Buy

NovoCure Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
NovoCure Limited
NovoCure Limited
-32.26%
-37.62%
-40.14%
-32.97%
49.92%
Stryker Corporation
Stryker Corporation
-4.07%
14.24%
19.87%
34.25%
55.23%
Boston Scientific Corp.
Boston Scientific Corp.
-4.61%
11.05%
28.02%
29.56%
63.29%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-4.31%
17.36%
-12.41%
10.7%
79.94%
Abbott Laboratories
Abbott Laboratories
-7.47%
-2.09%
-12.2%
10.87%
62.42%
Medtronic PLC
Medtronic PLC
-7.31%
8.7%
-13.34%
-17.5%
-3.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
NovoCure Limited
NovoCure Limited
NA
NA
-0.47
-1.93
-0.32
-0.08
0.0
4.07
Stryker Corporation
Stryker Corporation
40.46
40.46
2.85
10.16
0.16
0.06
0.01
44.51
Boston Scientific Corp.
Boston Scientific Corp.
85.67
85.67
2.53
1.95
0.05
0.04
0.0
12.42
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
34.91
34.91
3.07
2.55
0.25
0.13
0.0
9.87
Abbott Laboratories
Abbott Laboratories
31.16
31.16
18.76
4.4
0.16
0.06
0.02
21.28
Medtronic PLC
Medtronic PLC
29.28
29.28
3.04
5.28
0.07
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
NovoCure Limited
NovoCure Limited
Sell
$8.7B
49.92%
NA
-26.98%
Stryker Corporation
Stryker Corporation
Buy
$105.5B
55.23%
40.46
13.86%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$73.9B
63.29%
85.67
6.92%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.6B
79.94%
34.91
27.07%
Abbott Laboratories
Abbott Laboratories
Buy
$180.4B
62.42%
31.16
13.98%
Medtronic PLC
Medtronic PLC
Buy
$111.4B
-3.5%
29.28
12.03%

Institutional Holdings

  • FMR Inc

    14.82%

  • Capital World Investors

    13.21%

  • Vanguard Group Inc

    9.15%

  • Baillie Gifford & Co Limited.

    8.10%

  • Capital Research & Mgmt Co - Division 3

    7.49%

  • BlackRock Inc

    7.16%

Corporate Announcements

  • NovoCure Limited Earnings

    NovoCure Limited’s price-to-earnings ratio stands at None

    Read More

Company Information

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Organization
NovoCure Limited
Employees
1320
CEO
Mr. William F. Doyle
Industry
Health Technology

Discover More

FAQs